DiaMedica Therapeutics Inc. (NASDAQ:DMAC) is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
Stock Performance
Shares of DiaMedica Therapeutics Inc. traded up $ 0.18 or 4.09 percent on Tuesday, reaching $ 4.58 with volume of 33.00 thousand shares. DiaMedica Therapeutics Inc. has traded high as $ 4.58 and has cracked $ 4.24 on the downward trend
According to the previous trading day, closing price of $ 4.58, representing a 135.29 % increase from the 52 week low of $ 1.87 and a 50 % decrease over the 52 week high of $ 8.80.
The company has a market capital of $ 85.83 million and is part of the Healthcare sector and Biotechnology industry.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company is also developing DM199 for the treatment vascular dementia; and DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels.
